Sascha Young Kupke

This paper develops a fed-batch production process for OP7 chimera DIPs, achieving higher virus titers and bioactivity compared to batch production, with potential for GMP manufacturing.

This study engineers a modified DIP by truncating NS1 to enhance antiviral activity, showing improved inhibition of IAV replication and IFN response.

This paper develops a multiscale model of IAV and OP7 coinfection, revealing MOI-dependent antiviral mechanisms and predicting therapeutic efficacy.

This study demonstrates that OP7, an unconventional influenza A defective interfering particle, effectively inhibits viral replication in human lung cells through both direct interference and IFN induction, supporting its potential as an antiviral agent.